DR info

臨床試験数 : 90 / 薬物数 : 122 - (DrugBank : 47) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 144

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE
   Alkahest, Inc.
      2020   Phase 2   EUCTR2019-001059-37-BG   Bulgaria;Germany;
      2019   Phase 2   EUCTR2019-001059-37-DE   Bulgaria;Germany;
AC-203 Topical Ointment
   TWi Biotechnology, Inc.
      2017   Phase 2   NCT03286582   Taiwan;
AKST4290
   Alkahest, Inc.
      2020   Phase 2   NCT04499235   Germany;
      2020   Phase 2   EUCTR2019-001059-37-BG   Bulgaria;Germany;
      2019   Phase 2   EUCTR2019-001059-37-DE   Bulgaria;Germany;
ARAVA
   CHU de Limoges
      2007   -   EUCTR2007-003545-32-FR   France;
Apremilast
   Universitair Medisch Centrum Groningen
      2019   Phase 2   EUCTR2018-002564-10-NL   Netherlands;
Avdoralimab
   CHU NICE
      2020   Phase 2   EUCTR2020-002912-34-FR   France;
Avdoralimab (IPH5401)
   Centre Hospitalier Universitaire de Nice
      2020   Phase 2   NCT04563923   France;
Azathioprine
   Washington University School of Medicine
      2022   Phase 2   NCT05263505   United States;
Azathioprine or Mycophenolate mofetil
   University Hospital Muenster
      1997   Phase 2   NCT00431119   Germany;
BIV009
   Bioverativ, a Sanofi company
      2015   Phase 1   NCT02502903   Austria;
Baricitinib 2 MG [Olumiant]
   Washington University School of Medicine
      2022   Phase 2   NCT05263505   United States;
Benralizumab
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-000287-32-IT   Australia;Bulgaria;France;Germany;Israel;Italy;Japan;Spain;United States;
   AstraZeneca
      2021   Phase 3   NCT04612790   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United States;
   AstraZeneca AB
      2021   Phase 3   EUCTR2020-000287-32-GR   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United States;
      2021   Phase 3   EUCTR2020-000287-32-FR   Australia;Bulgaria;France;Germany;Israel;Italy;Japan;Spain;United States;
      2021   Phase 3   EUCTR2020-000287-32-DE   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United States;
      2020   Phase 3   EUCTR2020-000287-32-BG   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United States;
   Hibi Kazushige
      2021   Phase 3   JPRN-jRCT2071210014   Australia;Bulgaria;France;Germany;Israel;Italy;Japan;Spain;United States;
Bertilimumab
   Immune Pharmaceuticals
      2016   Phase 2   NCT02226146   Israel;United States;
Blood test
   Centre Hospitalier Universitaire, Amiens
      2019   Phase 4   NCT03926377   -
Bone densitometry
   Centre Hospitalier Universitaire, Amiens
      2019   Phase 4   NCT03926377   -
CC-10004
   Universitair Medisch Centrum Groningen
      2019   Phase 2   EUCTR2018-002564-10-NL   Netherlands;
Carboxymethylcellulose with ionic silver (Aquacel Ag)
   Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
      2015   -   NCT02365675   Mexico;
Cellcept® in autoimmune bullous dermatoses
   University Hospital, Limoges
      2016   Phase 3   NCT02993133   France;
Cellulose acetate with petrolatum
   Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
      2015   -   NCT02365675   Mexico;
Clobetasol Propionate cream treatment
   University Hospital, Rouen
      2015   Phase 4   NCT02360202   France;
Clobetasol Topical Ointment
   TWi Biotechnology, Inc.
      2017   Phase 2   NCT03286582   Taiwan;
Clobetasol propionate
   Centre Hospitalier Universitaire, Amiens
      2019   Phase 4   NCT03926377   -
Clobetasol propionate + Methotrexate
   University Hospital, Montpellier
      2008   Phase 3   NCT02313870   France;
Clobetasol propionate alone
   University Hospital, Montpellier
      2008   Phase 3   NCT02313870   France;
Collagenase
   National Taiwan University Hospital
      2012   Phase 1   NCT02202642   Taiwan;
Cotton
   CHU de Reims
      2015   -   NCT02874079   France;
Cotton gauze with petrolatum
   Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
      2015   -   NCT02365675   Mexico;
Cultivated oral mucosal epithelial sheet transplantation
   Seoul National University Hospital
      2014   Phase 1/Phase 2   NCT02149732   Korea, Republic of;
Cyclophosphamide 50Mg Oral Tablet
   University Hospital, Rouen
      2019   Phase 3   NCT03295383   France;
Cyclosporine
   The First Affiliated Hospital of Kunming Medical University
      2020   Phase 4   ChiCTR2000029007   China;
   UNIVERSITA' CAMPUS BIOMEDICO
      2008   -   EUCTR2008-000480-41-IT   Italy;
DERMOVAL
   CHU de Limoges
      2007   -   EUCTR2007-003545-32-FR   France;
DF2156A
   DOMPE' s.p.a.
      2011   -   EUCTR2011-000756-42-IT   Germany;Italy;
   Dompé Farmaceutici S.p.A
      2012   Phase 2   NCT01571895   Germany;Italy;
   Dompé s.p.a.
      -   -   EUCTR2011-000756-42-DE   Germany;Italy;
Data report
   Assistance Publique Hopitaux De Marseille
      2018   -   NCT03636763   France;
Dermoval
   University Hospital, Rouen
      2001   -   NCT00213421   France;
Dexamethasone 0.5mg/5ml solution in Mucolox™
   University of California, San Francisco
      2020   Phase 2   NCT04540133   United States;
Doxycycline
   University of Nottingham
      2009   Phase 4   EUCTR2007-006658-24-GB   Germany;United Kingdom;
   Universitätsklinikum Schleswig-Holstein
      2009   Phase 4   EUCTR2007-006658-24-DE   Germany;United Kingdom;
Dupilumab
   Regeneron Pharmaceuticals
      2021   -   NCT04776694   -
      2020   Phase 2/Phase 3   NCT04206553   Australia;France;Germany;Japan;United States;
Dupixent
   Regeneron Pharmaceuticals, Inc.
      2020   Phase 2;Phase 3   EUCTR2019-003520-20-FR   Australia;France;Germany;Japan;Spain;United States;
      2020   Phase 2;Phase 3   EUCTR2019-003520-20-DE   Australia;France;Germany;Japan;United States;
EFG PH20 SC
   argenx
      2022   Phase 2/Phase 3   NCT05267600   -
Fasenra
   AstraZeneca AB
      2021   Phase 3   EUCTR2020-000287-32-GR   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United States;
      2021   Phase 3   EUCTR2020-000287-32-DE   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United States;
      2020   Phase 3   EUCTR2020-000287-32-BG   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United States;
Gold
   the Second Affiliated Hospital, Xi'an Jiaotong University
      2018   -   ChiCTR1800017560   China;
Halometasone
   Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
      2009   -   ChiCTR-IOR-15007146   China;
   The First Affiliated Hospital of Kunming Medical University
      2020   Phase 4   ChiCTR2000029007   China;
INTERLEUKIN-2
   Dermatology Hospital, Southern Medical University
      2020   Phase 0   ChiCTR2000028707   China;
IPH5401
   CHU NICE
      2020   Phase 2   EUCTR2020-002912-34-FR   France;
Imatinib
   Kabashima Kenji
      2018   Phase 0   JPRN-jRCTs051180069   Japan;
Impedance analysis
   University Hospital, Rouen
      2015   Phase 4   NCT02360202   France;
Ixekizumab
   Mayo Clinic
      2017   Phase 2   NCT03099538   United States;
Ladarixin
   DOMPE' s.p.a.
      2011   -   EUCTR2011-000756-42-IT   Germany;Italy;
   Dompé s.p.a.
      -   -   EUCTR2011-000756-42-DE   Germany;Italy;
Large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP
   Tanta University
      2020   Phase 2/Phase 3   NCT04744623   Egypt;
Leflunomide
   University Hospital, Limoges
      2007   Phase 2   NCT00802243   France;
MEDI-563
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-000287-32-IT   Australia;Bulgaria;France;Germany;Israel;Italy;Japan;Spain;United States;
   AstraZeneca AB
      2021   Phase 3   EUCTR2020-000287-32-GR   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United States;
      2021   Phase 3   EUCTR2020-000287-32-FR   Australia;Bulgaria;France;Germany;Israel;Italy;Japan;Spain;United States;
      2021   Phase 3   EUCTR2020-000287-32-DE   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United States;
      2020   Phase 3   EUCTR2020-000287-32-BG   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United States;
MTX
    Chinese Academy of Medical Sciences
   Institute of dermatology
   Institute of dermatology, Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003538   China;
Mabthéra
   CHU-Hôpitaux de Rouen
      2009   -   EUCTR2008-005266-31-FR   France;
Mathéra
   CHU-Hôpitaux de Rouen
      2009   -   EUCTR2008-005266-31-FR   France;
Mepolizumab (a-IL-5 antibody)
   University Hospital Inselspital, Berne
      2013   Phase 2   NCT01705795   Switzerland;
Methotrexate
   Washington University School of Medicine
      2022   Phase 2   NCT05263505   United States;
Methylprednisolone
   The First Affiliated Hospital of Kunming Medical University
      2020   Phase 4   ChiCTR2000029007   China;
Minocycline
   Institute of dermatology, Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003592   China;
Mometasone furoate
   Alkahest, Inc.
      2020   Phase 2   NCT04499235   Germany;
Mycophenolate
   Washington University School of Medicine
      2022   Phase 2   NCT05263505   United States;
Myfortic 180 mg Filmtabletten
   Georg-August-Universität Göttingen, Bereich Humanmedizin
      2005   Phase 2   EUCTR2005-001827-12-DE   Germany;
NNC0215-0384
   CHU NICE
      2020   Phase 2   EUCTR2020-002912-34-FR   France;
NPB-01
   Nihon Pharmaceutical Co., Ltd
      2011   Phase 3   NCT01408550   Japan;
      2008   Phase 2   NCT00809822   Japan;
Nanocrystalline silver (Acticoat)
   Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
      2015   -   NCT02365675   Mexico;
Nicotinamide
   Institute of dermatology, Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003592   China;
Nomacopan (rVA576)
   AKARI Therapeutics
      2021   Phase 3   NCT05061771   -
Omalizumab
   University of Iowa
      2007   Phase 4   NCT00472030   United States;
Oral corticosteroids (OCS)
   Regeneron Pharmaceuticals
      2020   Phase 2/Phase 3   NCT04206553   Australia;France;Germany;Japan;United States;
Otezla
   Universitair Medisch Centrum Groningen
      2019   Phase 2   EUCTR2018-002564-10-NL   Netherlands;
Prednisolone
   University of Nottingham
      2009   Phase 4   EUCTR2007-006658-24-GB   Germany;United Kingdom;
   Universitätsklinikum Schleswig-Holstein
      2009   Phase 4   EUCTR2007-006658-24-DE   Germany;United Kingdom;
Prednisone
    Chinese Academy of Medical Sciences
   CHU-Hôpitaux de Rouen
      2009   -   EUCTR2008-005266-31-FR   France;
   Institute of dermatology
   Institute of dermatology, Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003538   China;
   The First Affiliated Hospital of Kunming Medical University
      2020   Phase 4   ChiCTR2000029007   China;
   University of Iowa
      2007   Phase 4   NCT00472030   United States;
   argenx
      2022   Phase 2/Phase 3   NCT05267600   -
QGE031
   Novartis Pharma AG
      2012   -   EUCTR2012-003370-10-AT   Austria;Germany;Taiwan;United States;
   Novartis Pharma Services AG
      2013   Phase 2   EUCTR2012-003370-10-FR   Austria;France;Germany;Taiwan;United States;
      2013   -   EUCTR2012-003370-10-DE   Austria;Germany;Taiwan;United States;
   Novartis Pharmaceuticals
      2013   Phase 2   NCT01688882   Austria;France;Germany;Japan;Taiwan;United States;
RESTASIS
   UNIVERSITA' CAMPUS BIOMEDICO
      2008   -   EUCTR2008-000480-41-IT   Italy;
RVA576
   AKARI Therapeutics
      2018   Phase 2   NCT04035733   Germany;Netherlands;
   Akari Therapeutics Plc
      2021   Phase 3   EUCTR2020-005987-67-DE   Germany;United States;
   Akari Therapeutics Plc.
      2018   Phase 2   EUCTR2017-002836-18-NL   Germany;Netherlands;
      2018   Phase 2   EUCTR2017-002836-18-DE   Germany;Netherlands;
Radiographs of the thoracic and lumbar spine
   Centre Hospitalier Universitaire, Amiens
      2019   Phase 4   NCT03926377   -
Riboflavin
   Joseph B. Ciolino, MD
      2012   Phase 1/Phase 2   NCT01582880   United States;
Rituximab
   Department of Dermatology,Keio University School of Medicine
      2014   Phase 1,2   JPRN-UMIN000015451   Japan;
   Duke University
      2005   Phase 1/Phase 2   NCT00286325   United States;
   Kanaoka Miwa
      2014   -   JPRN-jRCTs031180220   Japan;
   Research group of rare intractable dermatologial disorder
      2010   Phase 2   JPRN-UMIN000004428   Japan;
   University of Alabama at Birmingham
      2006   Phase 1/Phase 2   NCT00584935   United States;
Rituximab 1g IV
   University Hospital, Rouen
      2019   Phase 3   NCT03295383   France;
Rituximab combined with Omalizumab
   University of California, Davis
      2023   Phase 3   NCT04128176   United States;
Simvastatin-ratiopharm®
   Philipps-Universität Marburg
      2013   -   EUCTR2011-004361-32-DE   Germany;
Solu-Medrone
   Moorfields Eye Hospital NHS Foundation Trust
      2005   Phase 4   EUCTR2005-002391-14-GB   United Kingdom;
Tildrakizumab Prefilled Syringe
   Brigham and Women's Hospital
      2020   Early Phase 1   NCT04465292   -
Topical infliximab
   James Chodosh, MD, MPH
      2014   Phase 1/Phase 2   NCT02126020   Canada;United States;
Treatment systemic therapy (prednisone)
   CHU de Reims
      2013   -   NCT02837965   France;
Treatment with systemic therapy (doxycycline)
   CHU de Reims
      2013   -   NCT02837965   France;
Treatment with systemic therapy (methotrexate)
   CHU de Reims
      2013   -   NCT02837965   France;
Treatment with systemic therapy (prednisone)
   CHU de Reims
      2013   -   NCT02837965   France;
Treatment with topical superpotent corticosteroid therapy
   CHU de Reims
      2013   -   NCT02837965   France;
Tripterygium
   Institute of dermatology, Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003592   China;
Ustekinumab
   CHU de Reims
      2020   Phase 2   NCT04117932   France;